Importance De novo bullous pemphigoid (BP) is a rare immune-mediated adverse event
from immune checkpoint inhibitors (ICIs) that can necessitate permanent discontinuation of
the anticancer therapy, but the risk factors for developing this toxic effect are unknown.
Objective To compare potential risk factors for BP in patients treated with ICIs who did and
did not develop BP. Design, Setting, and Participants This cohort and nested propensity
score–matched case-control study was conducted at the Dana-Farber Cancer Institute …